{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T22:54:01Z","timestamp":1793660041676,"version":"4.5.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["2022\/MRF2019812"],"award-info":[{"award-number":["2022\/MRF2019812"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Critically ill patients with shock receiving vasopressor or inotrope therapy in ICU are often exposed to relative hypotension, which is quantified as percentage blood pressure deficit relative to usual pre-illness blood pressure. Whether minimising such blood pressure deficit, by adjusting blood pressure targets according to patients\u2019 pre-illness blood pressure (individualised blood pressure target strategy), can improve clinical outcomes remains unclear. Therefore, we are conducting a multicenter randomised controlled trial, the REACT SHOCK RCT, comparing individualised blood pressure targets to standard care among critically ill patients with shock.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The REACT SHOCK RCT is an international, multicenter, parallel-group, randomised, standard-care controlled, clinical superiority trial that will be conducted in up to 35 ICUs in Australia, Ireland, Singapore, UK and USA. In total, 1260 patients, receiving vasopressor therapy for non-haemorrhagic shock in ICU, will be randomly assigned to individualised mean arterial blood pressure (MAP) targets (determined as an average of 2\u20135 recent pre-illness blood pressure readings within last 3\u00a0years, with a MAP target range of 55 to 95\u00a0mmHg) or standard care (default MAP target of 65\u00a0mmHg) in a 1:1 ratio. The REACT SHOCK RCT is anticipated to complete recruitment by 2028. The primary endpoint is all-cause 14-day mortality. Secondary endpoints are major adverse kidney events by day 14, all-cause 90-day mortality, survival time to 14\u00a0days and 90\u00a0days, and renal replacement\u00a0therapy free days by day 28.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>The REACT SHOCK RCT is the first international multicenter randomised clinical trial designed to ascertain whether an individualised blood pressure target strategy is superior to standard care for critically ill patients with shock. This trial will generate evidence that may influence current recommendations for MAP targets during management of shock in ICU. The pre-specified protocol summary and statistical analysis plan are presented here.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>Prospectively registered on Australian and New Zealand Clinical Trials Registry (ANZCTRN 12623000044628); ClinicalTrials.gov ID NCT05850962 dated 29th April 2023.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13063-025-09142-9","type":"journal-article","created":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T14:06:30Z","timestamp":1760450790000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["REACT SHOCK trial protocol and analysis plan\u2014a multicenter randomised controlled trial comparing individualised blood pressure target versus standard blood pressure target among critically ill patients with shock"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9090-8829","authenticated-orcid":false,"given":"Rakshit","family":"Panwar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Gibberd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Oldmeadow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravindranath","family":"Tiruvoipati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"\u00c5neman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Kansal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"REACT SHOCK investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,14]]},"reference":[{"issue":"8","key":"9142_CR1","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1001\/jama.2016.0287","volume":"315","author":"M Singer","year":"2016","unstructured":"Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315(8):801\u201310. https:\/\/doi.org\/10.1001\/jama.2016.0287.","journal-title":"JAMA"},{"issue":"16","key":"9142_CR2","doi-asserted-by":"publisher","first-page":"e232","DOI":"10.1161\/CIR.0000000000000525","volume":"136","author":"S van Diepen","year":"2017","unstructured":"van Diepen S, Katz JN, Albert NM, et al. Contemporary management of cardiogenic shock: a scientific statement from the American Heart Association. Circulation. 2017;136(16):e232\u201368. https:\/\/doi.org\/10.1161\/CIR.0000000000000525.","journal-title":"Circulation"},{"issue":"7","key":"9142_CR3","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1007\/s12630-017-0878-0","volume":"64","author":"B Rochwerg","year":"2017","unstructured":"Rochwerg B, Hylands M, Moller M, et al. CCCS-SSAI WikiRecs Clinical Practice Guideline: vasopressor blood pressure targets in critically ill adults with hypotension. Can J Anaesth. 2017;64(7):763\u20135. https:\/\/doi.org\/10.1007\/s12630-017-0878-0.","journal-title":"Can J Anaesth"},{"issue":"11","key":"9142_CR4","doi-asserted-by":"publisher","first-page":"e1063","DOI":"10.1097\/CCM.0000000000005337","volume":"49","author":"L Evans","year":"2021","unstructured":"Evans L, Rhodes A, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Crit Care Med. 2021;49(11):e1063\u2013143. https:\/\/doi.org\/10.1097\/CCM.0000000000005337.","journal-title":"Crit Care Med"},{"issue":"5","key":"9142_CR5","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1097\/shk.0000000000001033","volume":"49","author":"R Panwar","year":"2018","unstructured":"Panwar R. Untreated relative hypotension measured as perfusion pressure deficit during management of shock and new-onset acute kidney injury- a literature review. Shock. 2018;49(5):497\u2013507. https:\/\/doi.org\/10.1097\/shk.0000000000001033.","journal-title":"Shock"},{"issue":"1","key":"9142_CR6","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s40635-019-0280-z","volume":"7","author":"M Ostermann","year":"2019","unstructured":"Ostermann M, Schneider A, Rimmele T, et al. Report of the first AKI Round Table meeting: an initiative of the ESICM AKI Section. Intensive Care Med Exp. 2019;7(1):69. https:\/\/doi.org\/10.1186\/s40635-019-0280-z.","journal-title":"Intensive Care Med Exp"},{"issue":"5","key":"9142_CR7","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/j.jcrc.2013.05.009","volume":"28","author":"R Panwar","year":"2013","unstructured":"Panwar R, Lanyon N, Davies AR, Bailey M, Pilcher D, Bellomo R. Mean perfusion pressure deficit during the initial management of shock\u2013an observational cohort study. J Crit Care. 2013;28(5):816\u201324. https:\/\/doi.org\/10.1016\/j.jcrc.2013.05.009.","journal-title":"J Crit Care"},{"issue":"10","key":"9142_CR8","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1164\/rccm.201912-2316OC","volume":"202","author":"R Panwar","year":"2020","unstructured":"Panwar R, Tarvade S, Lanyon N, et al. Relative hypotension and adverse kidney-related outcomes among critically ill patients with shock. A multicenter, prospective cohort study. Am J Respir Crit Care Med. 2020;202(10):1407\u201318. https:\/\/doi.org\/10.1164\/rccm.201912-2316OC.","journal-title":"Am J Respir Crit Care Med"},{"issue":"10","key":"9142_CR9","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1164\/rccm.202007-2728ED","volume":"202","author":"HB Gershengorn","year":"2020","unstructured":"Gershengorn HB. Sometimes it is okay to get personal: individualizing targets in critical care. Am J Respir Crit Care Med. 2020;202(10):1334\u20136. https:\/\/doi.org\/10.1164\/rccm.202007-2728ED.","journal-title":"Am J Respir Crit Care Med"},{"key":"9142_CR10","doi-asserted-by":"publisher","unstructured":"Panwar R, Sullohern B, Shiel E, Alexis Brown C, Quail A. Validity of a protocol to estimate patients' pre-morbid basal blood pressure. Blood Press.2017:1\u20139. https:\/\/doi.org\/10.1080\/08037051.2017.1358055.","DOI":"10.1080\/08037051.2017.1358055"},{"key":"9142_CR11","doi-asserted-by":"publisher","first-page":"154052","DOI":"10.1016\/j.jcrc.2022.154052","volume":"70","author":"R Panwar","year":"2022","unstructured":"Panwar R, Van Haren F, Cazzola F, Nourse M, Brinkerhoff G, Quail A. Standard care versus individualized blood pressure targets among critically ill patients with shock: a multicenter feasibility and preliminary efficacy study. J Crit Care. 2022;70:154052. https:\/\/doi.org\/10.1016\/j.jcrc.2022.154052.","journal-title":"J Crit Care"},{"key":"9142_CR12","doi-asserted-by":"publisher","unstructured":"Khanna A, English SW, Wang XS, et al. Angiotensin II for the treatment of vasodilatory shock. N Engl J Med. 2017. https:\/\/doi.org\/10.1056\/NEJMoa1704154.","DOI":"10.1056\/NEJMoa1704154"},{"issue":"6","key":"9142_CR13","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1007\/s00134-017-4732-1","volume":"43","author":"JA Kellum","year":"2017","unstructured":"Kellum JA, Zarbock A, Nadim MK. What endpoints should be used for clinical studies in acute kidney injury? Intensive Care Med. 2017;43(6):901\u20133. https:\/\/doi.org\/10.1007\/s00134-017-4732-1.","journal-title":"Intensive Care Med"},{"issue":"7","key":"9142_CR14","doi-asserted-by":"publisher","DOI":"10.1007\/s10916-016-0528-z","volume":"40","author":"MW Semler","year":"2016","unstructured":"Semler MW, Rice TW, Shaw AD, et al. Identification of major adverse kidney events within the electronic health record. J Med Syst. 2016;40(7):167. https:\/\/doi.org\/10.1007\/s10916-016-0528-z.","journal-title":"J Med Syst"},{"key":"9142_CR15","unstructured":"Group. KDIGOKCW. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Inter Suppl. 2013;3:1\u2013150."},{"issue":"9","key":"9142_CR16","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1503\/cmaj.071366","volume":"178","author":"D Cook","year":"2008","unstructured":"Cook D, Lauzier F, Rocha MG, Sayles MJ, Finfer S. Serious adverse events in academic critical care research. CMAJ. 2008;178(9):1181\u20134. https:\/\/doi.org\/10.1503\/cmaj.071366. (Apr 22).","journal-title":"CMAJ"},{"key":"9142_CR17","doi-asserted-by":"publisher","first-page":"i5078","DOI":"10.1136\/bmj.i5078","volume":"355","author":"N Lineberry","year":"2016","unstructured":"Lineberry N, Berlin JA, Mansi B, et al. Recommendations to improve adverse event reporting in clinical trial publications: a joint pharmaceutical industry\/journal editor perspective. BMJ. 2016;355:i5078. https:\/\/doi.org\/10.1136\/bmj.i5078.","journal-title":"BMJ"},{"key":"9142_CR18","doi-asserted-by":"publisher","first-page":"e7586","DOI":"10.1136\/bmj.e7586","volume":"346","author":"AW Chan","year":"2013","unstructured":"Chan AW, Tetzlaff JM, G\u00f8tzsche PC, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013;346:e7586. https:\/\/doi.org\/10.1136\/bmj.e7586.","journal-title":"BMJ"},{"key":"9142_CR19","doi-asserted-by":"crossref","unstructured":"Knaus WA, Wagner DP, Draper EA, et al. The APACHE III prognostic system. Risk prediction of hospital mortality for critically ill hospitalized adults. Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S. Chest. 1991;100(6):1619\u201336.","DOI":"10.1378\/chest.100.6.1619"},{"issue":"46","key":"9142_CR20","doi-asserted-by":"publisher","first-page":"4391","DOI":"10.1093\/eurheartj\/ehaa665","volume":"41","author":"B Redfors","year":"2020","unstructured":"Redfors B, Gregson J, Crowley A, et al. The win ratio approach for composite endpoints: practical guidance based on previous experience. Eur Heart J. 2020;41(46):4391\u20139. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa665.","journal-title":"Eur Heart J"},{"issue":"23","key":"9142_CR21","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1001\/jama.2023.24391","volume":"330","author":"Y Freund","year":"2023","unstructured":"Freund Y, Viglino D, Cachanado M, et al. Effect of noninvasive airway management of comatose patients with acute poisoning: a randomized clinical trial. JAMA. 2023;330(23):2267\u201374. https:\/\/doi.org\/10.1001\/jama.2023.24391.","journal-title":"JAMA"},{"key":"9142_CR22","doi-asserted-by":"publisher","unstructured":"Tavares CAM, Azevedo LCP, Rea-Neto \u00c1, et al. Dapagliflozin for critically ill patients with acute organ dysfunction: the DEFENDER randomized clinical trial. JAMA. 2024. https:\/\/doi.org\/10.1001\/jama.2024.10510.","DOI":"10.1001\/jama.2024.10510"},{"issue":"1","key":"9142_CR23","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.jclinepi.2008.07.006","volume":"62","author":"DN Wijeysundera","year":"2009","unstructured":"Wijeysundera DN, Austin PC, Hux JE, Beattie WS, Laupacis A. Bayesian statistical inference enhances the interpretation of contemporary randomized controlled trials. J Clin Epidemiol. 2009;62(1):13-21.e5. https:\/\/doi.org\/10.1016\/j.jclinepi.2008.07.006.","journal-title":"J Clin Epidemiol"},{"key":"9142_CR24","doi-asserted-by":"publisher","unstructured":"Zampieri FG, Casey JD, Shankar-Hari M, Harrell FE, Harhay MO. Using Bayesian methods to augment the interpretation of critical care trials. An overview of theory and example reanalysis of the alveolar recruitment for acute respiratory distress syndrome trial. Am J Respir Crit Care Med. 2021;203(5):543\u2013552. https:\/\/doi.org\/10.1164\/rccm.202006-2381CP.","DOI":"10.1164\/rccm.202006-2381CP"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-025-09142-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-025-09142-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-025-09142-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:11:59Z","timestamp":1761127919000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-025-09142-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,14]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["9142"],"URL":"https:\/\/doi.org\/10.1186\/s13063-025-09142-9","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,14]]},"assertion":[{"value":"7 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed or verbal consent will be obtained from participants or their legal surrogates. Following are the approval numbers:Hunter New England Local Health District Human Research Ethics Committee 2018\/ETH00019.Singapore National Healthcare group Domain Specific Review Board 2023\/00341.Ireland Health Research Consent Declaration Committee 23\u2013004-AF1.University of New Mexico Health Sciences Human Research Review Committee 23\u2013180.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"409"}}